Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.
<h4>Background</h4>In the Strategies for Management of Anti-Retroviral Therapy trial, all-cause mortality was higher for participants randomized to intermittent, CD4-guided antiretroviral treatment (ART) (drug conservation [DC]) than continuous ART (viral suppression [VS]).We hypothesize...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-10-01
|
| Series: | PLoS Medicine |
| Online Access: | https://doi.org/10.1371/journal.pmed.0050203 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849686705623269376 |
|---|---|
| author | Lewis H Kuller Russell Tracy Waldo Belloso Stephane De Wit Fraser Drummond H Clifford Lane Bruno Ledergerber Jens Lundgren Jacqueline Neuhaus Daniel Nixon Nicholas I Paton James D Neaton INSIGHT SMART Study Group |
| author_facet | Lewis H Kuller Russell Tracy Waldo Belloso Stephane De Wit Fraser Drummond H Clifford Lane Bruno Ledergerber Jens Lundgren Jacqueline Neuhaus Daniel Nixon Nicholas I Paton James D Neaton INSIGHT SMART Study Group |
| author_sort | Lewis H Kuller |
| collection | DOAJ |
| description | <h4>Background</h4>In the Strategies for Management of Anti-Retroviral Therapy trial, all-cause mortality was higher for participants randomized to intermittent, CD4-guided antiretroviral treatment (ART) (drug conservation [DC]) than continuous ART (viral suppression [VS]).We hypothesized that increased HIV-RNA levels following ART interruption induced activation of tissue factor pathways, thrombosis, and fibrinolysis.<h4>Methods and findings</h4>Stored samples were used to measure six biomarkers: high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), amyloid A, amyloid P, D-dimer, and prothrombin fragment 1+2. Two studies were conducted: (1) a nested case-control study for studying biomarker associations with mortality, and (2) a study to compare DC and VS participants for biomarker changes. For (1), markers were determined at study entry and before death (latest level) for 85 deaths and for two controls (n = 170) matched on country, age, sex, and date of randomization. Odds ratios (ORs) were estimated with logistic regression. For each biomarker, each of the three upper quartiles was compared to the lowest quartile. For (2), the biomarkers were assessed for 249 DC and 250 VS participants at study entry and 1 mo following randomization. Higher levels of hsCRP, IL-6, and D-dimer at study entry were significantly associated with an increased risk of all-cause mortality. Unadjusted ORs (highest versus lowest quartile) were 2.0 (95% confidence interval [CI], 1.0-4.1; p = 0.05), 8.3 (95% CI, 3.3-20.8; p < 0.0001), and 12.4 (95% CI, 4.2-37.0; p < 0.0001), respectively. Associations were significant after adjustment, when the DC and VS groups were analyzed separately, and when latest levels were assessed. IL-6 and D-dimer increased at 1 mo by 30% and 16% in the DC group and by 0% and 5% in the VS group (p < 0.0001 for treatment difference for both biomarkers); increases in the DC group were related to HIV-RNA levels at 1 mo (p < 0.0001). In an expanded case-control analysis (four controls per case), the OR (DC/VS) for mortality was reduced from 1.8 (95% CI, 1.1-3.1; p = 0.02) to 1.5 (95% CI, 0.8-2.8) and 1.4 (95% CI, 0.8-2.5) after adjustment for latest levels of IL-6 and D-dimer, respectively.<h4>Conclusions</h4>IL-6 and D-dimer were strongly related to all-cause mortality. Interrupting ART may further increase the risk of death by raising IL-6 and D-dimer levels. Therapies that reduce the inflammatory response to HIV and decrease IL-6 and D-dimer levels may warrant investigation. |
| format | Article |
| id | doaj-art-94126b3e390d483697f043bcb24cf96a |
| institution | DOAJ |
| issn | 1549-1277 1549-1676 |
| language | English |
| publishDate | 2008-10-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Medicine |
| spelling | doaj-art-94126b3e390d483697f043bcb24cf96a2025-08-20T03:22:37ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762008-10-01510e20310.1371/journal.pmed.0050203Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.Lewis H KullerRussell TracyWaldo BellosoStephane De WitFraser DrummondH Clifford LaneBruno LedergerberJens LundgrenJacqueline NeuhausDaniel NixonNicholas I PatonJames D NeatonINSIGHT SMART Study Group<h4>Background</h4>In the Strategies for Management of Anti-Retroviral Therapy trial, all-cause mortality was higher for participants randomized to intermittent, CD4-guided antiretroviral treatment (ART) (drug conservation [DC]) than continuous ART (viral suppression [VS]).We hypothesized that increased HIV-RNA levels following ART interruption induced activation of tissue factor pathways, thrombosis, and fibrinolysis.<h4>Methods and findings</h4>Stored samples were used to measure six biomarkers: high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), amyloid A, amyloid P, D-dimer, and prothrombin fragment 1+2. Two studies were conducted: (1) a nested case-control study for studying biomarker associations with mortality, and (2) a study to compare DC and VS participants for biomarker changes. For (1), markers were determined at study entry and before death (latest level) for 85 deaths and for two controls (n = 170) matched on country, age, sex, and date of randomization. Odds ratios (ORs) were estimated with logistic regression. For each biomarker, each of the three upper quartiles was compared to the lowest quartile. For (2), the biomarkers were assessed for 249 DC and 250 VS participants at study entry and 1 mo following randomization. Higher levels of hsCRP, IL-6, and D-dimer at study entry were significantly associated with an increased risk of all-cause mortality. Unadjusted ORs (highest versus lowest quartile) were 2.0 (95% confidence interval [CI], 1.0-4.1; p = 0.05), 8.3 (95% CI, 3.3-20.8; p < 0.0001), and 12.4 (95% CI, 4.2-37.0; p < 0.0001), respectively. Associations were significant after adjustment, when the DC and VS groups were analyzed separately, and when latest levels were assessed. IL-6 and D-dimer increased at 1 mo by 30% and 16% in the DC group and by 0% and 5% in the VS group (p < 0.0001 for treatment difference for both biomarkers); increases in the DC group were related to HIV-RNA levels at 1 mo (p < 0.0001). In an expanded case-control analysis (four controls per case), the OR (DC/VS) for mortality was reduced from 1.8 (95% CI, 1.1-3.1; p = 0.02) to 1.5 (95% CI, 0.8-2.8) and 1.4 (95% CI, 0.8-2.5) after adjustment for latest levels of IL-6 and D-dimer, respectively.<h4>Conclusions</h4>IL-6 and D-dimer were strongly related to all-cause mortality. Interrupting ART may further increase the risk of death by raising IL-6 and D-dimer levels. Therapies that reduce the inflammatory response to HIV and decrease IL-6 and D-dimer levels may warrant investigation.https://doi.org/10.1371/journal.pmed.0050203 |
| spellingShingle | Lewis H Kuller Russell Tracy Waldo Belloso Stephane De Wit Fraser Drummond H Clifford Lane Bruno Ledergerber Jens Lundgren Jacqueline Neuhaus Daniel Nixon Nicholas I Paton James D Neaton INSIGHT SMART Study Group Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Medicine |
| title | Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. |
| title_full | Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. |
| title_fullStr | Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. |
| title_full_unstemmed | Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. |
| title_short | Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. |
| title_sort | inflammatory and coagulation biomarkers and mortality in patients with hiv infection |
| url | https://doi.org/10.1371/journal.pmed.0050203 |
| work_keys_str_mv | AT lewishkuller inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT russelltracy inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT waldobelloso inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT stephanedewit inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT fraserdrummond inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT hcliffordlane inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT brunoledergerber inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT jenslundgren inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT jacquelineneuhaus inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT danielnixon inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT nicholasipaton inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT jamesdneaton inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection AT insightsmartstudygroup inflammatoryandcoagulationbiomarkersandmortalityinpatientswithhivinfection |